Methylene blue inhibits angiogenesis in chick chorioallontoic membrane through a nitric oxide-independent mechanism

Journal of Cellular and Molecular Medicine

Volumn 10, Issue 2, 2006, Pages 493-498

  Zacharakis, N ^a   Tone, P ^b   Flordellis, C S ^a   Maragoudakis, M E ^a   Tsopanoglou, Nikos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

Angiogenesis; Chick chorioallantoic membrane; Guanylyl cyclase; Methylene blue; Nitric oxide

Indexed keywords

ENZYME INHIBITOR; METHYLENE BLUE; NITRIC OXIDE;

ANGIOGENESIS; ANIMAL; ARTICLE; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; METHYLENE BLUE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE;

EID: 33747179292     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2006.tb00414.x     Document Type: Article

References (29)

1. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol. 2006; 38: 333-57.
2. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 1996; 211: 1-6.
3. Ziche M. Nitric oxide and angiogenesis. In: Maragoudakis ME, editor. Angiogenesis models, modulators and clinical applications. New York and London: Plenum Press; 1998; 298: 297-306.
4. Pipili-Synetos E. Nitric oxide: A promoter or inhibitor of angiogenesis. In: Maragoudakis ME, editor. Angiogenesis models, modulators and clinical applications. New York and London: Plenum Press; 1998; 298: 307-319.
5. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993; 45: 367-74.
6. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrate and amyl nitrite. Can J Physiol Pharmacol. 1981; 59: 150-6.
7. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J. 1993; 14: 22-6.
8. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol. 1993; 264: C1302-7.
9. Maragoudakis ME, Haralabopoulos G, Tsopanoglou NE, Pipili-Synetos E. Validation of collagenous protein synthesis as an index for angiogenesis with the use of morphological methods. Microvasc Res. 1995; 50: 215-22.
10. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981; 218: 739-49.
11. Pipili-Synetos E, Sakkoula E, Maragoudakis ME. Nitric oxide is involved in the regulation of angiogenesis. Br J Pharmacol. 1993; 108: 855-7.
12. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Andriopoulou P, Peristeris P, Maragoudakis ME. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol. 1994; 111: 894-902.
13. Chiang SC, Cheng CH, Moulton KS, Kasznica JM, Moulton SL. TNP-470 inhibits intraabdominal adhesion formation. J Pediatr Surg. 2000; 35: 189-96.
14. Kluger Y, Weinbroum A, Ben-Avraham R, Galili Y, Klausner J, Radau M. Reduction in formation of peritoneal adhesions by methylene blue in rats: a dose response study. Eur J Surg. 2000; 166: 568-71.
15. Faber P, Ronald A, Millar BW. Methylthioninium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass. Anaesthesia 2005; 60: 575-87.
16. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA. 1990; 87: 5193-7.
17. Deininger MH, Wybranietz WA, Graepler FTC, Lauer UM, Meyermann R, Schluesener HJ. Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. FASEB J. 2003; 17: 1267-76.
18. Pan S-L, Guh J-H, Peng C-Y, Wang S-W, Chang Y-L, Cheng F-C, Chang J-H, Kuo S-C, Lee F-Y, Teng C-M. YC-1 [3-(5'-Hydroxymethyl-2;-fury10-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo. J Pharmacol Exp Ther. 2005; 314: 35-42.
19. Duenas ET, Keck R, De Vos A, Jones AJ, Cleland JL. Comparison between light induced and chemically induced oxidation of rhVEGF. Pharm Res. 2001; 18: 1455-60.
20. Lewis C, Scouten WH. Photooxidation of methionine with immobilized methylene blue as photooxidizer. Biochim Piophys Acta. 1976; 444: 326-30.
21. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest. 2001; 108: 349-55.
22. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001; 114: 853-65.
23. Presta M, Leali D, Stabile H, Ronca R, Carmozzi L, Coco E, Moroni E, Liekens S, Rusnati M. Heparin derivatives as angiogenesis inhibitors. Curr Pharmac Design. 2003; 9: 553-66.
24. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res. 1982; 9: 247-8.
25. Farmdale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylene blue. Biochim Biophys Acta. 1986; 883: 173-7.
26. Clifton HJ, Leikin JB. Methylene blue. Am J Ther. 2003; 10: 289-91.
27. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB. Methylene blue increases myocardial function in septic shock. Crit Care Med. 1995; 23: 1363-70.
28. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann Emerg Med. 1997; 30: 240.
29. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology and clinical management. Ann Emerg Med. 1999; 34: 646-56.